Cost-effectiveness of apixaban versus low molecular weight heparin/vitamin k antagonist for the treatment of venous thromboembolism and the prevention of recurrences

BACKGROUND: Prior analyses beyond clinical trials are yet to evaluate the projected lifetime benefit of apixaban treatment compared to low-molecular-weight heparin (LMWH)/vitamin K antagonist (VKA) for treatment of venous thromboembolism (VTE) and prevention of recurrences. The objective of this stu...

Descripción completa

Detalles Bibliográficos
Autores principales: Lanitis, Tereza, Leipold, Robert, Hamilton, Melissa, Rublee, Dale, Quon, Peter, Browne, Chantelle, Cohen, Alexander T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5259920/
https://www.ncbi.nlm.nih.gov/pubmed/28114939
http://dx.doi.org/10.1186/s12913-017-1995-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5259920/
https://www.ncbi.nlm.nih.gov/pubmed/28114939
http://dx.doi.org/10.1186/s12913-017-1995-8

Ejemplares similares